Osimertinib

Other brands, manufacturers, strengths, packs and regulatory evidence have not been individually verified. No additional version list is published.

Other brands, manufacturers, strengths, packs and regulatory evidence have not been individually verified. No additional version list is published.

Other brands, manufacturers, strengths, packs and regulatory evidence have not been individually verified. No additional version list is published.

Other brands, manufacturers, strengths, packs and regulatory evidence have not been individually verified. No additional version list is published.

Osimertinib is an EGFR tyrosine kinase inhibitor used in certain patients with EGFR mutation-positive non-small cell lung cancer. Approved uses, versions, prices and payment arrangements vary by country.

FDA — Tagrisso prescribing information

Osimertinib is the generic name; Tagrisso is the AstraZeneca originator brand, also commonly called 泰瑞沙 in Chinese. Country-specific records need separate checks.

FDA — Tagrisso prescribing information · PMDA — Tagrisso product information

Official US, Japanese and Indian sources list 40 mg and 80 mg tablets. Strength information is not a personal dosing recommendation.

FDA — Tagrisso prescribing information · PMDA — Tagrisso product information · CDSCO — SEC Oncology meeting record

This page has not completed NMPA product and local supply verification; specific versions and stock cannot be confirmed here. Consult local clinicians and licensed pharmacies.

The current NHSA formulary notice and original attachment are retained. The drug entry, payment restrictions and individual reimbursement still require item-level verification.

NHSA — 2025 formulary implementation notice · NHSA — 2025 formulary attachment (item review pending)

CDSCO has AstraZeneca 40 mg / 80 mg records and a pharmacy price listing exists. This does not establish stock or your eligibility to buy or obtain cross-border supply.

CDSCO — SEC Oncology meeting record · Tata 1mg — Tagrisso 80 mg

This page includes a Tagrisso commercial listing. Other brands, manufacturers, packs and approval evidence have not been individually verified, so no list is published.

Tata 1mg — Tagrisso 80 mg

Osimertinib is an ingredient name; Tagrisso is a brand. A matching name or commercial listing alone does not establish approval, quality or interchangeability. Verify the product and consult a clinician or pharmacist.

FDA — Tagrisso prescribing information

Yes. PMDA lists 40 mg / 80 mg, the ingredient and authorization holder. Personal access and current stock need separate confirmation.

PMDA — Tagrisso product information

Verified historical 2023 official prices are JPY 9,670 per 40 mg tablet and JPY 18,540.20 per 80 mg tablet. Current 2026 pricing remains pending; these are not current pharmacy quotes or out-of-pocket costs.

MHLW — historical reimbursement price notice

The FDA label records initial US approval in 2015 and 40 mg / 80 mg tablets. Approval does not establish current stock at a pharmacy.

FDA — Tagrisso prescribing information

A dedicated FDA generic-approval review has not been completed here. We make no definitive claim and do not label commercial products from other countries as FDA-approved.

Pack size, strength, insurance, channels, assistance, taxes and payment systems affect prices. Commercial references and historical official prices cannot identify the cheapest personal option on their own.

Drugs.com Price Guide · Tata 1mg — Tagrisso 80 mg · MHLW — historical reimbursement price notice

Lawful access depends on the patient’s location, prescription status, source and destination rules, provider requirements and the specific medicine. MedAccessly can research case-specific requirements but does not guarantee import or supply.